Slide 1 Carlo Garufi [email protected] Oncologia Medica A Istituto Regina Elena - Roma Advanced Metastatic Disease Which biological targeted agent and for whom? Slide 2 Saltz…

Slide 1 G. Cartenì Direttore U.O.S.C. di Oncologia Medica A.O.R.N. A. Cardarelli Napoli Roma, 22 febbraio 2013 Highlights in the management of renal cell carcinoma Criteria…

Slide 1 Synthetic Genome Brings New Life to Bacterium (Gibson DG et Al., Science, 20 May, 2010) Slide 2 Targeted therapy nella terapia del cancro del colon retto metastatico.…

Slide 1 Quale sarà il ruolo di Denosumab: la 1° linea di trattamento, l’associazione all’ac. zolendronico o la 2° linea ? G. Cartenì Direttore U.O.S.C. di Oncologia…

Slide 1 Alessandra Felici, Oncologia Medica A Istituto Regina Elena Rome The near future: molecular targeted therapies for metastatic prostate cancer NEW PERSPECTIVES IN…

2007-2008 Lower GI Overview Chair: Charles D. Blanke, M.D., F.A.C.P. Systemic Therapy Provincial Program Leader, B.C. Cancer Agency Chief, Division of Medical Oncology, University…

Role of CXCR4 and VEGF expression and metastatic locoregional lymphnodes in rectal carcinoma Tatangelo F.*, Avallone A.**, Delrio P.°, Scala S.§, Botti G.* S.C. Anatomia…

Updated results, multivariate and subgroups analysis confirm improved activity and efficacy for FOLFOXIRI vs FOLFIRI in the G.O.N.O. randomized phase III study in metastatic…

Venous Thrombosis and Long Term Use of Central Venous Catheter in Cancer Patients treated with Chemotherapy: Epidemiology and Risk Factors Giuseppe Curigliano Dipartimento…

ASCO Annual Meeting 2012 PHASE II STUDY OF PANITUMUMAB (P) IN COMBINATION WITH FOLFOXIRI AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): HIGH ACTIVITY IN…